[1]
|
M. Lacroix, D. Abi-Said, R. Fourney, Z. L. Gokaslan, W. Shi, F. DeMont, F. F. Lang and E. McCutcheon, “A Multivariate Analysis of 416 Patients with Glioblastoma Multiforme: Prognosis, Extent of Resection, and Survival,” Journal of Neurosurgery, Vol. 95, No. 2, 2001, pp. 190- 198. doi:10.3171/jns.2001.95.2.0190
|
[2]
|
G. E. Keles, B. Anderson and M. S. Berger, “The Effect of Extent of Resection on Time to Tumor Progression and Survival in Patients with Glioblastoma Multiforme of the Cerebral Hemisphere,” Surgery Neurology, Vol. 52, No. 4, 1999, pp. 371-379. doi:10.1016/S0090-3019(99)00103-2
|
[3]
|
W. Stummer, H. Reulen, T. Meinel, U. Pichlmeier, W. Schumacher and J. Tonn, “Extent Resection and Survival in Glioblastoma Multiforme: Identification of and Adjustment for Bias,” Neurosurgery, Vol. 62, 2008, pp. 564-576. doi:10.1227/01.neu.0000317304.31579.17
|
[4]
|
J. R. Simpson, J. Horton, C. Scott, W. J. Curran, P. Rubin and J. Fischbach, “Influence of Location and Extent of Surgical Resection on Survival of Patients with Glioblastoma Multiforme: Results of Three Consecutive Radiation Therapy Oncology Group (RTOG) Clinical Trials,” International Journal of Radiation Oncology Biology Physics, Vol. 2, 1993, pp. 239-244.
doi:10.1016/0360-3016(93)90203-8
|
[5]
|
P. Yuile, O. Dent, R. Cook, M. Biggs and N. Little, “Survival of Glioblastoma Patients Related to Presenting Symptoms, Brain Site and Treatment Variables,” Journal of Clinical Neuroscience, Vol. 13, No. 7, 2006, pp. 747-751. doi:10.1016/j.jocn.2005.10.011
|
[6]
|
C. R. Miller and A. Perry, “Glioblastoma Morphologic and Molecular Genetic Diversity,” Arch Pathology Laboratory Medicine, Vol. 131, No. 3, 2007, pp. 397-406.
|
[7]
|
J. F. Mineo, A. Bordron, M. Baroncini, C. Ramirez, C. A. Maurage, S. Blond and P. Dam-Hieu, “Prognosis Factors of Survival Time in Patients with Glioblastoma Multiforme: A Multivariate Analysis of 340 Patients,” Acta Neurochirurgica, Vol. 149, 2007, pp. 245-253.
doi:10.1007/s00701-006-1092-y
|
[8]
|
C. Jagger, C. Gillies, F. Moscone, E. Cambois, H. Van Oyen, W. Nusselder and J. Robine, “Inequalities in Healthy Life Years in the 25 Countries of the European Union in 2005: A Cross-National Meta-Regression Analysis,” The Lancet, Vol. 372, No. 9656, 2008, pp. 2124-2131. doi:10.1016/S0140-6736(08)61594-9
|
[9]
|
M. Wrensch, T. Rice, R. Miike, A. McMillan, K. R. Lamborn, K. Aldape and M. D. Prados, “Diagnostic, Treatment, and Demographic Factors Influencing Survival in a Population-Based Study of Adult Glioma Patients in the San Francisco Bay Area,” Neuron-Oncology, Vol. 26, No. 4, 2006, pp. 12-26.
doi:10.1215/S1522851705000268
|
[10]
|
S. M. Chang and F. G. Barker II, “Marital Status, Treatment and Survival in Patients with Glioblastoma-Multiforme: A Population-Based Study,” Cancer, Vol. 104, 2005, pp. 1975-1984. doi:10.1002/cncr.21399
|
[11]
|
P. D. Inskip, R. E. Tarone, E. E. Hatch, T. C. Wilcosky, H. A. Fine, P. M. Black, J. S. Loeffler, W. R. Shapiro, R. G. Selker and M. S. Linet, “Sociodemographic Indicators and Risk of Brain Tumors,” International Journal of Epidemiology, Vol. 32, No. 2, 2003, pp. 225-233.
doi:10.1093/ije/dyg051
|
[12]
|
P. Salander, A. T. Bergenheim, K. Hamberg, R. Henriksson, “Pathways from Symptoms to Medical Care: A Descriptive Study of Symptom Development and Obstacles to Early Diagnosis in Brain Tumors Patients,” Family Practice, Vol. 16, No. 2, 1999, pp. 143-148.
doi:10.1093/fampra/16.2.143
|
[13]
|
R. Stupp, W. P. Mason, M. J. Bent, M. Weller, M. J. B. Taphoorn and K. Belanger, “Radiotherapy plus Conco- mitant and Adjuvant Temozolomide for Glioblastoma,” New England Journal of Medicine, Vol. 352, 2005, pp. 987-996. doi:10.1056/NEJMoa043330
|
[14]
|
F. T. Vertosick Jr, R. G. Selker, I. F. Pollack and V. Arena, “The Treatment of Intracranial Malignant Gliomas Using Orally Administered Tamoxifen Therapy: Preliminary Results in a Series of 'Faleid' Patients,” Neurosurgery, Vol. 30, 1992, pp. 897-903.
doi:10.1227/00006123-199206000-00014
|
[15]
|
C. J. Wheeler, J. S. Yu and K. L. Black, “Cellular Immunity in the Treatment of Brain Tumors,” Clinical Neurosurgery, Vol. 51, No. 3, 2004, pp. 132-139.
|
[16]
|
S. Puget and J. T. Rutka, “Malignant Brain Tumors: Two Steps Forward,” Clinical Neurosurgery, Vol. 54, 2007, pp. 4-9.
|
[17]
|
J. W. Henson, “Treatment of Glioblastoma Multiforme,” Arch Neurology, Vol. 63, No. 3, 2006, pp. 337-341.
doi:10.1001/archneur.63.3.337
|
[18]
|
M. Salcman, H. Scholtz, R. S. Kaplan and S. Kulik, “Long-Term Survival in Patients with Malignant Astrocytoma,” Neurosurgery, Vol. 34, No. 2, 1994, pp. 213- 219. doi:10.1227/00006123-199402000-00002
|
[19]
|
K. L. Chandler, M. D. Prados, M. B. A. Malec and C. B. Wilson, “Long-Term Survival in Patients with Glioblastoma Multiforme,” Neurosurgery, Vol. 32, 1993, pp. 716-720. doi:10.1227/00006123-199305000-00003
|
[20]
|
D. Krex, B. Klink, C. Hartmann, A. Von Deimling, T. Pietsch, M. Simon and M. Sabel, “Long-Term Survival with Glioblastoma Multiforme,” Brain, Vol. 130, No. 10, 2007, pp. 2596-2606. doi:10.1093/brain/awm204
|
[21]
|
W. T. Curry Jr., B. S. Carter and F. G. Barker, “Racial, Ethic, and Socioeconomic Disparities in Patient Outcome after Craniotomy for Tumor in Adult Patient in the United State, 1988-2004,” Neurosurgery, Vol. 66, No. 3, 2010, pp. 427-438. doi:10.1227/01.NEU.0000365265.10141.8E
|